Cor Vasa 2024, 66(2):105-111 | DOI: 10.33678/cor.2024.025

(Focused on heart failure treatment according to the updated 2023 guidelines)

Jaroslav Brotánek
Interní klinika, 1. a 3. lékařská fakulta Univerzity Karlovy a Fakultní Thomayerova nemocnice, Praha, Česká republika

Acute and chronic heart failure remains a very serious and high priority problem in contemporary cardiology. New, modern drugs are currently emerging in the treatment of heart failure while the possibilities of their further use for this diagnosis are being expanded. These findings have been summarized in the 2023 update of the European Society of Cardiology Guidelines for heart failure. This article provides a brief summary of the new developments in pharmacotherapy based on the above recommendations.

Keywords: Acute and chronic heart failure, Diuretics, Ferric derisomaltose, Finerenone, Gliflozins, Sacubitril/valsartan

Received: March 17, 2024; Accepted: March 17, 2024; Prepublished online: June 2, 2012; Published: April 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Brotánek J. (Focused on heart failure treatment according to the updated 2023 guidelines). Cor Vasa. 2024;66(2):105-111. doi: 10.33678/cor.2024.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. Go to original source... Go to PubMed...
    2. van Riet EE, Hooes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016;18:242-252. Go to original source... Go to PubMed...
    3. Hradec J, Býma S. Chronické srdeční selhání. Kap Kardiol 2015;7:89-93.
    4. Seferović PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018;20:853-872. Go to original source... Go to PubMed...
    5. Gerber Y, Weston SA, Redfield MM, et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med 2015;175:996-1004. Go to original source... Go to PubMed...
    6. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev 2017;3:7-11. Go to original source... Go to PubMed...
    7. Barasa A, Schaufelberger M, Lappas G, et al. Heart failure in young adults: 20-year trends in hospitalisation, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:25-32. Go to original source... Go to PubMed...
    8. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-1146. Go to original source... Go to PubMed...
    9. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023;44:3627-3639. Go to original source... Go to PubMed...
    10. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451-461. Go to original source... Go to PubMed...
    11. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413-1424. Go to original source... Go to PubMed...
    12. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089-1098. Go to original source... Go to PubMed...
    13. Solomon SD, McMurray JJV, Anand IS, PARAGON-HF Investigators and Committees. Angiotensin-neprilysininhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609-1620. Go to original source... Go to PubMed...
    14. Vaduganathan M, Claggett BL, Desai AS, et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril/valsartan compared with valsartan in HFpEF. J Am Coll Cardiol 2020;75:245-254. Go to original source... Go to PubMed...
    15. Mentz RJ, Ward JH, Hernandez AF, et al. Angiotensin- -Neprilysin Inhibition in Patients with Mildly Reduced or Preserved Ejection Fraction and Worsening Heart Failure. J Am Coll Cardiol 2023;82:1-12. Go to original source... Go to PubMed...
    16. Abdin A, Anker SD, Butler J, et al. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail 2021;8:4444-4453. Go to original source... Go to PubMed...
    17. Čillíková K. Léčba srdečního selhání očima nových guidelines ESC. Medical Tribune 2023. Dostupné z: https://www.tribune.cz/archiv/lecba-srdecniho-selhani-ocima-novych-guidelines-esc/
    18. Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised trial. Lancet 2022;400:1938-1952. Go to original source... Go to PubMed...
    19. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568-574. Go to original source... Go to PubMed...
    20. Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 2022;146:289-298. Go to original source... Go to PubMed...
    21. Patil T, Halsey E, Kaur A, et al. Changes in diuretic medication prescribing and surrogate laboratory parameters after initiating empagliflozin in veterans (CHAMPION Cohort Study). Clin Drug Invest 2023;43:61-74. Go to original source... Go to PubMed...
    22. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022;387:1185-1195. Go to original source... Go to PubMed...
    23. Trullàs JC, Morales-Rull JL, Casado J, et al. Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 2023;44:411-421. Go to original source... Go to PubMed...
    24. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-1446. Go to original source... Go to PubMed...
    25. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023;388:117-127. Go to original source... Go to PubMed...
    26. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295-2306. Go to original source... Go to PubMed...
    27. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2021;384:129-139. Go to original source... Go to PubMed...
    28. Urbánek K. Finerenon: farmakologický profil. Klin Farmakol Farm 2023;37:29-32. Go to original source...
    29. Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non- -steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021;42:152-161. Go to original source... Go to PubMed...
    30. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol 2017;12:2032-2045. Go to original source... Go to PubMed...
    31. González-Juanatey JR, Górriz JL, Ortiz A, et al. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med 2023;55:502-513. Go to original source... Go to PubMed...
    32. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219-2229. Go to original source... Go to PubMed...
    33. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021;385:2252-2263. Go to original source... Go to PubMed...
    34. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474-484. Go to original source...
    35. Kalra PR, Cleland JGF, Petrie MC, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective,randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199-2209. Go to original source... Go to PubMed...
    36. Bergström A, Andersson B, Edner M, et al. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 2004;6:453-461. Go to original source... Go to PubMed...
    37. Lund LH, Benson L, Dahlström U, et al. Association Between Use of β-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JAMA 2014;312:2008-2018. Go to original source... Go to PubMed...
    38. Yamamoto K, Origasa H, Hori M, et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013;15:110-118. Go to original source... Go to PubMed...
    39. Adityawati AAD, Rahimah AF, Rohman MS, et al. The Effect of Bisoprolol on Heart Failure Preserved Ejection Fraction / Hfpef Patient's Quality Of Life. Heart Sci J 2021;2:25-30. Go to original source...
    40. Lam PH, Gupta N, Dooley DJ, et al. Role of high-dose beta- -blockers in patients with heart failure with preserved ejection fraction and elevated heart rate. Am J Med 2018;131:1473-1481. Go to original source... Go to PubMed...
    41. Málek F. Optimalizace léčby pacientů se srdečním selháním. Med promoci 2020;1:28-31.
    42. Lábr K, Špinar J, Pařenica J, et al. Betablokátory v registru chronického srdečního selhání FAR NHL. Kardiol Rev Int Med 2017;19:68-72.
    43. Doležal T. Bisoprolol v terapii srdečního selhání. Remedia 2002;12:219-220.
    44. Špinar J, Špinarová L, Vítovec J. Duální inhibice AT1 receptoru pro angiotensin II a neprilysinu aneb sacubitril-valsartan. Interní Med 2019;21:118-124. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes